The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 110.60
Bid: 110.20
Ask: 111.00
Change: 0.00 (0.00%)
Spread: 0.80 (0.726%)
Open: 114.00
High: 114.00
Low: 110.00
Prev. Close: 110.60
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXECUTIVE CHANGES: All change at Aura Energy amid ASX spin-out plan

Mon, 22nd Nov 2021 15:57

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Monday and not separately reported by Alliance News:

----------

Aura Energy Ltd - gold and uranium explorer in Sweden and Mauritania - Revamps board and management as part of push to become a uranium producer. Phil Mitchell, a former Rio Tinto PLC and Anglo American PLC executive, will be named non-executive chair at Aura's annual general meeting on December 21. Peter Reeve will leave the board, as he moves from chief executive officer of Aura to CEO of wholly owned gold subsidiary Archaean Greenstone Gold Pty Ltd. Reeve will lead the spin-out of Archaean as a separate listing on the ASX in Sydney in 2022. Aura shareholders will received shares in Archaean as part of the process. Aura will look for a new CEO within six months to focus on taking the Tiris uranium project in Mauritania into production. Warren Mundine and Bryan Dixon, both accountants experienced in junior mining companies, will become independent non-executive directors, while Martin Rogers and Peter Ward will depart the board at the AGM.

----------

Jersey Oil & Gas PLC - explorer in UK North Sea - Installs former leadership team of Ithaca Energy, a North Sea oil and gas producer that had been listed on AIM, in senior positions. Promotes Non-Executive Director Les Thomas to chair, replacing Marcus Stanton, who will remain as a non-executive director. Thomas was CEO of Ithaca until 2020. Hires Graham Forbes as chief financial officer. Forbes had been CFO of Ithaca. Richard Smith, who was corporate development director at Ithaca, joins Jersey Oil as chief commercial officer. All effective immediately. Company says it remains in active discussions with "multiple counterparties" regarding the farm-out of the Greater Buchan Area in the central North Sea.

----------

Xpediator PLC - Braintree, England-based freight management services provider in UK and central and eastern Europe - Rob Ross steps down as CEO immediately, with Non-Executive Director Wim Pauwels made interim CEO while a search for a successor is conducted. Ross had joined Xpediator as CFO at the start of 2020. Pauwels formerly was chief regional officer for Yusen Logistics Europe. Xpediator says trading remains positive and in line with market expectations for the full year.

----------

e-Therapeutics PLC - Oxford, England-based computational drug discovery - Karl Keegan will step down as CFO on December 31 "to focus in the near term on extremely difficult family circumstances in Ireland". Non-Executive Director Michael Bretherton will become interim CFO while the company looks for a new CFO. Bretherton, a former PriceWaterhouse accountant, has been a director of seven other AIM-listed companies, e-Therapeutics notes.

----------

Grainger PLC - Newcastle-based residential landlord - Promotes Eliza Pattinson to director of investments for asset management, managing Grainger's portfolio of 9,727 rental homes, effective immediately. Rehires Steven Clark as director of investments for acquisitions. Clark joins in mid-February next year from Lendlease Europe, where he is residential investment director. He had left Grainger as commercial finance director in April 2020.

----------

Hiscox Ltd - Hamilton, Bermuda-based insurer - Hires Donna DeMaio as independent non-executive director, replacing Caroline Foulger, who will retire at the 2022 annual general meeting after nine years. Hiscox holds its AGM in May. DeMaio was chief operating officer for American International Group Inc's General Insurance division.

----------

Syncona Ltd - investment trust focused on healthcare - Hires Julie Cherrington and Cristina Csimma as non-executive directors, starting February 1 next year. Cherrington was CEO of biotechnology companies in the US, Canada and Australia, including Arch Oncology and Que Oncology. Csimma is executive chair of drug developer Forendo Pharma Ltd.

----------

Great Western Mining Corp PLC - gold, silver and copper explorer and developer in US state of Nevada - Hires James Blight as exploration manager, joining next Monday. Blight is a qualified person for mineral reporting purposes and has worked on projects in West Africa, Saudi Arabia, Ethiopia, Mongolia and Sweden.

----------

Utilico Emerging Markets Trust PLC - invests in infrastructure, utilities and related sectors in emerging markets - Hires Isabel Liu as independent non-executive director, starting immediately. Liu is an experienced infrastructure investor, Utilico says. She was managing director of the Asia-Pacific investment business of recently acquired infrastructure investor John Laing Group PLC and currently is a non-executive director of Schroder Oriental Income Fund Ltd.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
5 Feb 2021 08:01

Syncona investment Achilles upbeat on safety review of trials

(Sharecast News) - Healthcare investor Syncona said on Friday that its portfolio company Achilles Therapeutics, which is developing precision T-cell therapies to treat solid tumours, had announced that an independent data and safety monitoring committee had completed the first review of the ongoing, first-in-human phase 1 and 2 'CHIRON' and 'THETIS' trials.

Read more
6 Jan 2021 09:30

Syncona Investee Autolus To Focus On Adult Leukemia Programme in 2021

Syncona Investee Autolus To Focus On Adult Leukemia Programme in 2021

Read more
6 Jan 2021 08:36

Syncona upbeat on developments at Autolus

(Sharecast News) - Life science investor Syncona updated the market on its portfolio company Autolus on Wednesday, announcing that it would prioritise the development of the 'AUTO1' programme for adult acute lymphoblastic leukemia (ALL), based on the positive data generated in its phase 1 and 2 studies to date and a high unmet medical need.

Read more
21 Dec 2020 15:43

UK EXECUTIVE CHANGE SUMMARY: Ferguson Taps Former Ashtead, Bunzl Execs

UK EXECUTIVE CHANGE SUMMARY: Ferguson Taps Former Ashtead, Bunzl Execs

Read more
19 Nov 2020 10:12

Syncona Portfolio Companies Boost Interim Result; Launches New Company

Syncona Portfolio Companies Boost Interim Result; Launches New Company

Read more
19 Nov 2020 08:16

Syncona reports improved performance for past six months as clinical trials resume

(Sharecast News) - Healthcare company Syncona reported a "robust" performance for the six months up to 30 September in which its net assets reached a value of £1,366.7m at 203,4p per share and a net asset value total return of 9.6% in the period.

Read more
12 Nov 2020 15:55

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
2 Nov 2020 16:54

UK EXECUTIVE CHANGE SUMMARY: Kakuzi Acts To Prevent Human Rights Abuse

UK EXECUTIVE CHANGE SUMMARY: Kakuzi Acts To Prevent Human Rights Abuse

Read more
30 Oct 2020 10:06

Syncona Investee Freeline Posts Widened Interim Loss On Higher Costs

Syncona Investee Freeline Posts Widened Interim Loss On Higher Costs

Read more
30 Oct 2020 09:21

Syncona portfolio company sees interim losses widen

(Sharecast News) - Healthcare investment firm Syncona said on Friday that portfolio business Freeline Therapeutics had seen interim losses widen as a result of increased research and development costs.

Read more
14 Sep 2020 17:21

UK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation

UK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation

Read more
10 Aug 2020 09:19

Syncona Life Science Portfolio Boosted By Autolus And Freeline

Syncona Life Science Portfolio Boosted By Autolus And Freeline

Read more
7 Aug 2020 09:44

Syncona Investee Freeline Therapeutics Prices IPO In New York

Syncona Investee Freeline Therapeutics Prices IPO In New York

Read more
7 Aug 2020 08:17

Syncona portfolio company Freeline prices US IPO

(Sharecast News) - Healthcare investment company Syncona announced on Friday that its portfolio company Freeline Therapeutics has priced its initial public offering in the United States.

Read more
3 Aug 2020 22:16

UK TRADING UPDATE SUMMARY: Bluebird To Buy Southern Gold Venture Stake

UK TRADING UPDATE SUMMARY: Bluebird To Buy Southern Gold Venture Stake

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.